News Image

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Provided By GlobeNewswire

Last update: Aug 13, 2024

FOSTER CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today positive preliminary clinical data for the cohort of patients with non-CNS MET fusion solid tumors from the Phase 2 SPARTA trial of vebreltinib.

Read more at globenewswire.com

APOLLOMICS INC

NASDAQ:APLM (8/29/2025, 8:06:36 PM)

After market: 4.12 +0.19 (+4.79%)

3.9317

-0.25 (-6.05%)


APOLLOMICS INC-27

NASDAQ:APLMW (8/29/2025, 8:06:37 PM)

After market: 0.007 0 (-10.26%)

0.0078

0 (-7.14%)



Find more stocks in the Stock Screener

Follow ChartMill for more